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Summary
The MATRix chemoimmunotherapy regimen is highly effective in patients
with newly diagnosed primary diffuse large B-cell lymphoma of the central
nervous system (PCNSL). However, nothing is known about its feasibility
and efficacy in everyday practice, where patients are more often older/frai-
ler than those enrolled in clinical trials. We conducted a retrospective study
addressing tolerability/efficacy of MATRix in 156 consecutive patients with
newly diagnosed PCNSL treated outside a clinical trial. Median age and
ECOG Performance Status of considered patients were 62 years (range 28–
78) and 2 (range 0–4). The overall response rate after MATRix was 79%.
Nine (6%) treatment-related deaths were recorded. After a median follow-
up of 27.4 months (95% confidence interval [CI] 24.4–31.9%), the two-
year progression-free and overall survival were 56% (95% CI 48.4–64.9%)
and 64.1% (95% CI 56.7–72.5%) respectively. Patients not eligible for the
IELSG32 trial were treated with lower dose intensity and had substantially
worse outcomes than those fulfilling inclusion criteria. This is the largest
series of PCNSL patients treated with MATRix outside a trial and recapitu-
lates the IELSG32 trial outcomes in the non-trial setting for patients who
fit the trial criteria. These data underscore the feasibility and efficacy of
MATRix as induction treatment for fit patients in routine practice.
Keywords: primary diffuse large B-cell lymphoma of the central nervous
system, induction treatment, MATRix regimen, routine clinical practice,
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Primary diffuse large B-cell lymphoma (DLBCL) of the cen-
tral nervous system (PCNSL) is an aggressive disease, which
accounts for 2–3% of all non-Hodgkin lymphomas and
approximately 4% of all primary CNS tumours (Ferreri
et al., 2003a; Rubenstein et al., 2008). Its incidence has risen
over the past 30 years, particularly in immunocompetent
individuals (Makino et al., 2006; Haldorsen et al., 2007).
High-dose methotrexate (HD-MTX)-based chemoim-
munotherapy is a widely accepted induction treatment
approach (Ferreri et al., 2009; Morris et al., 2013; Rubenstein
et al., 2013; Glass et al., 2016). IELSG32, a randomized trial
from the International Extranodal Lymphoma Study Group
(IELSG), compared three different induction chemoim-
munotherapy regimens in patients with newly diagnosed
PCNSL. This trial clearly showed that the MATRix combina-
tion (HD-MTX, cytarabine [AraC], thiotepa [TT], and ritux-
imab) followed by consolidation therapy significantly
improved outcomes in eligible patients aged 70 years or
younger (Ferreri et al., 2016, 2017). The MATRix protocol
(four cycles administered every three weeks) followed by
consolidation high-dose chemotherapy and autologous stem
cell transplantation (HDT-ASCT) or whole-brain radiother-
apy (WBRT) is now a widely used treatment regimen in
newly diagnosed PCNSL and serves as a benchmark for
future randomized trials. However, the IELSG32 trial was
restricted to patients aged 70 years or younger with Eastern
Cooperative Oncology Group Performance Status (ECOG
PS) ≤2 (and <65 years with ECOG PS ≤3), whereas many
patients encountered in routine practice are older and/or
frailer than those treated in prospective trials. Given that pre-
vious studies (Ferreri et al., 2003b; Abrey et al., 2006; Schorb
et al., 2013) have demonstrated inferior outcomes for PCNSL
patients who present with a poor ECOG PS and older age,
clinicians may be concerned about using such an intensive
regimen in this patient population. Furthermore, the out-
come of PCNSL patients treated outside the clinical trial set-
ting is inferior and not solely attributable to advanced age
and poorer ECOG PS (Zeremski et al., 2016). Thus, we
investigated clinical outcomes in routine practice of patients
with newly diagnosed PCNSL treated with the MATRix com-
bination as induction treatment.
Methods
Patient selection criteria and data collection
Inclusion criteria for this retrospective multicentre analysis
were: (i) de novo, histologically or cytologically proven PCNSL,
(ii) exclusion of systemic lymphoma by CT body scan and
bone marrow examination or PET scan, (iii) administration of
at least one cycle of the MATRix regimen; and (iv) MATRix
delivered outside a clinical trial. We included consecutive
patients treated at participating centres from the time when
MATRix was adopted in routine practice (four centres prior to
2014, and nine centres after 2014). Patients were selected for
treatment by the treating clinician, with no upper age limit or
exclusions based on ECOG PS, co-morbidities or other
patient-related characteristics. Individual patient data from 13
co-operating centres, treated by clinicians experienced in
PCNSL therapy, were collected using a pre-specified data
extraction tool including details on baseline characteristics,
treatment, toxicities, objective response, progression-free and
overall survival (75 variables in total). In addition, the total
denominator of all patients with newly diagnosed PCNSL at
the participating centres during the study period was recorded
to estimate the proportion of patients being considered for
treatment on a trial protocol or with treatment other than
MATRix. Data were checked for consistency and queries clari-
fied with the local treating physician before inclusion in the
central database. The study was conducted in accordance with
ethical principles that have their origin in the Declaration of
Helsinki, and that are consistent with Good Clinical Practice
(GCP). The study protocol was approved by the ethics com-
mittee of the University of Freiburg Medical Center.
PCNSL assessment
Staging work-up aimed to exclude systemic disease and to
define involvement of different CNS structures (i.e., brain,
eyes, meninges, spine, cranial nerves) followed recommenda-
tions of the International PCNSL Collaborative Group
(Abrey et al., 2005). Baseline and response assessment imag-
ing were performed in line with standard of care and in
accordance with international guidelines using gadolinium-
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enhanced brain MRI scans evaluated by experienced local
(neuro-)radiologists at each centre (Abrey et al., 2005).
Patients achieving complete remission (CR) or partial remis-
sion (PR) were categorized as treatment responders, whereas
stable disease (SD) or progressive disease (PD) were consid-
ered non-responders. The worst toxicity per organ, per
patient was considered. Effects of treatment on cognitive
function and quality of life were not routinely assessed.
Statistical analysis
We used descriptive statistics (frequencies with proportions,
medians and ranges where appropriate) to summarize patient
demographics, treatments and outcomes. A ‘dose reduction’
was defined as at least a 25% reduction of at least one
MATRix drug. The primary endpoint of this study was feasi-
bility of the MATRix protocol in routine practice including
treatment delivery rate, main toxicities and rate of successful
stem cell mobilization. Secondary endpoints included objec-
tive response rate, overall survival (OS; defined as time from
day 1 of first MATRix course to death or date of last follow-
up visit) and progression-free survival (PFS; defined as the
time from day 1 of first MATRix course to date of PD,
relapse or death, whichever occurred first, or date of last fol-
low-up visit). Both time-to-event endpoints were estimated
using the Kaplan–Meier method; all Kaplan–Meier plots were
created with 95% CIs for the respective survival estimate.
The principal eligibility criteria for the IELSG32 trial were
immunocompetent patients aged up to 65 years with ECOG
PS ≤3 or aged up to 70 years if ECOG PS was ≤2. Additional
exclusion criteria were relevant co-morbidities such as
glomerular filtration rate <60 ml/min, active hepatitis, con-
comitant cancer, and cardiac/pulmonary or hepatic co-mor-
bidities. To investigate a possible prognostic impact of these
key criteria, we stratified the cohort into patients that would/
would not have fulfilled these criteria. In an additional sensi-
tivity analysis, we conducted the same analysis as described
above, but only considered the combination of age and ECOG
PS to define eligibility (age up to 65 years with ECOG PS ≤3
or age up to 70 years if ECOG PS was ≤2). We used a Cox
regression model to investigate the prognostic impact of dose
reductions (as defined above: yes versus no) during the first
cycle in a landmark analysis in which we restricted the analysis
to those patients treated with at least two cycles of treatment.
This model was adjusted for the IELSG32 trial eligibility crite-
ria. Follow-up was estimated using the inverse Kaplan–Meier
method (Schemper & Smith, 1996). We followed an intention-
to-treat approach considering all included patients in the
denominator in our calculations. We describe proportions
irrespective of missing data which are also outlined separately.
We did not plan any formal statistical hypothesis testing;
therefore, all P values were considered exploratory. All sur-
vival estimates and hazard ratios (HRs) were accompanied
by 95% CIs. Statistical analyses were carried out using the
statistical software R version 3.5.1 (R Foundation for Statisti-
cal Computing, Vienna, Austria; www.r-project.org).
Results
Patient selection and baseline characteristics
Medical records of 427 potentially eligible patients were
screened at 13 European centres from three different countries
for the period July 2010 to June 2018. In total, 198/427
(464%) patients fulfilled the IELSG32 trial eligibility criteria
and 164 (83%) of those patients were treated with the MATRix
regimen of whom 54 patients were not included in our analysis
due to enrolment in the IELSG32 or IELSG43 trial. Further-
more, 229/427 (536%) patients did not fulfil IELSG32 trial
inclusion criteria and 46 (20%) of those patients were also suc-
cessfully treated with MATRix. The remaining 183 patients
were not considered eligible for the MATRix regimen by the
investigators for the following reasons: advanced age +/
impaired ECOG PS (>70 years, or >65 years with ECOG PS
>2) in 154 patients (841%), ECOG PS = 4 in six patients
(33%), co-morbidities in 17 patients (93%), and immuno-
suppression in six patients (33%). Moreover, 34 of the 198
patients fulfilling IELSG32 trial eligibility criteria were not trea-
ted with MATRix as an individual decision of the treating
physician in 22 patients (647%), due to death or pre-treat-
ment complications in eight patients (235%) and due to refu-
sal of therapy of one patient (3%). Three additional patients
(88%) were treated with other protocols as the histology
revealed low grade lymphoma in two and Burkitt lymphoma in
one patient (Fig 1). The median age of the 154 patients not
treated with MATRix due to advanced age +/ reduced PS was
77 years (range 65–91). In total, 156 of 427 (365%) screened
patients were finally included. Latest follow-up data were col-
lected in August 2019; following which the study database was
locked. The median age and ECOG Performance Status of the
156 patients were 62 years (range 28–78) and 2 (range 0–4)
respectively. Characteristics of the 156 included patients strati-
fied by the IELSG32 trial eligibility criteria are summarized in
Table I. Overall, 110 (705%) would have met the IELSG32 trial
eligibility criteria whereas 46 (295%) would have not. The
main reasons for not meeting the IELSG32 trial criteria were:
age over 70 years (21/156; 135%) and impaired performance
status (7/156; 45%). Among the 18 (115%) other reasons,
there were 13 patients with relevant co-morbidities and five
patients with acquired immunodeficiency (four human
immunodeficiency virus (HIV)-positive patients and one case
of post-transplant lymphoproliferative disorder) (Fig 1).
Treatment delivery of the MATRix regimen
Overall, 99/156 (628%) patients (including the reported four
HIV-positive patients) received all four planned cycles (Table II).
The main reasons for treatment interruption were PD (n = 14),
severe infectious complications (n = 15) and haematological
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toxicity (n = 2). During the first cycle, 93/156 (596%) patients
received the full doses of each MATRix component; in 2/156
(13%) patients, information on dose was missing, because they
were treated at a peripheral centre. The second cycle was given to
136 patients, and of these 69 (507%) received the full dose. Rates
were similar for patients who received three (62/116 [535%]
patients) or four (49/97 [505%] patients) MATRix courses. In
total, 37/156 (237%) received all four cycles without dose reduc-
tions. For all cycles, patients who would have not fulfilled the
IELSG32 trial eligibility criteria were more likely to receive
reduced doses compared to those fulfilling IELSG32 eligibility
(Table II). Only 5/46 (11%) patients who did not meet IELSG32
trial eligibility criteria received all four MATRix cycles at full
dose. The most common reasons for dose reduction during the
first cycle were reduced ECOG PS, co-existing co-morbidities
and age. Main reasons for dose reduction during subsequent
chemotherapy cycles were haematological toxicities, infectious
complications and reduced ECOG PS.
Toxicities of the MATRix regimen
The first cycle of MATRix was associated with the most sev-
ere toxicities with 10/156 (6%) patients requiring an admis-
sion to the intensive-care unit (ICU) because of life-
threatening infections, which was recorded in five of 46
(11%) patients who did not meet IELSG32 trial eligibility
criteria and in five of 110 (5%) patients who would have
been eligible. By contrast, there was only one ICU admission
during cycles 2–4. Severe complications (mostly infectious)
that did not require admission to ICU were reported in 44/
156 (28%) patients after the first course, in 23/136 (17%)
after the second, in 19/117 (16%) after the third, and in 11/
97 (11%) patients after the fourth course. None of the HIV-
positive patients suffered severe treatment-related complica-
tions. Other less severe side effects including haematological
toxicities and minor infections were recorded in 23 (15%)
(first course), 19 (14%) (second course), 16 (14%) (third
course), and 14 (14%) (fourth course) patients respectively.
Nine out of 156 patients died of toxicity during MATRix
treatment, equating to a treatment-related mortality (TRM)
of 6%: six died from infectious complications and three fol-
lowing cardiovascular events (clinical suspicion of fatal pul-
monary embolism in two patients, fatal stroke in one
patient). Seven patients died during cycle 1 (three had
received dose reductions due to advanced age/reduced
ECOG PS; five would have fulfilled IELSG32 trial eligibility
criteria) and two patients died during cycle 2 (one had
received dose-reduced therapy due to advanced age and co-
morbidities; the other one would have fulfilled IELSG32
trial eligibility criteria).
Fig 1. Flow chart of patient selection from 13 different European centres. In total, 210 (156 + 54) patients (49%) received the MATRix regimen,
whereas 83% of the patients eligible for the IELSG32 trial received MATRix and this regimen was also successfully delivered in 20% of the
patients who did not fulfil IELSG32 eligibility criteria. Abbreviations: PCNSL = primary diffuse large B-cell lymphoma of the central nervous sys-
tem; IELSG = International Extranodal Lymphoma Study Group; MATRix = high-dose-methotrexate, cytarabine, thiotepa, and rituximab;
PI = principal investigator; DLBCL = diffuse large B-cell lymphoma; ECOG PS = Eastern Cooperative Group Performance Status;
GFR = Glomerular filtration rate; PTLD = Post-transplant lymphoproliferative disorder; HIV = Human immunodeficiency virus;
COPD = Chronic obstructive pulmonary disease. [Colour figure can be viewed at wileyonlinelibrary.com]
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There were three further deaths not related to lymphoma
relapse (hepatic failure, septic encephalitis, and sudden death)
over six months after MATRix and all considered unrelated to
induction therapy. All three patients had undergone HDT-ASCT
consolidation and were in remission of PCNSL.
Treatment response to MATRix induction and type of
consolidation treatment
Results from brain MRI were available in 145 of 156 patients
(93%). Overall, 123 of 156 patients (79%; 95% CI 71–85%)
achieved an objective response (54 patients with CR and 69
with PR), six (4%) patients were reported with SD and 16
(10%) had documented PD. In 10 (6%) patients no data on
lymphoma response were available because of death or evi-
dence of clinical progression before first MRI assessment; all
10 cases were classified as non-responders for this analysis.
In one patient without clinical suspicion for progression,
brain MRI was still awaited at time of data lock. Successful
stem cell mobilization was performed in 116 of 123 (94%)
responders. In three of 123 patients (25%) stem cell harvest
was insufficient, the remaining four patients (35%) were
judged ineligible for HDT-ASCT and thus stem cell harvest
was not attempted. Different types of consolidation treat-
ment stratified by the IELSG32 trial eligibility criteria for all
patients are summarized in Table III.
Of those 123 patients achieving an objective response, 83
(675%) received consolidation treatment: 60 (488%)
patients underwent HDT-ASCT, 20 (162%) received WBRT,
two received conventionally dosed chemotherapy, and one
patient had lenalidomide maintenance treatment. Forty of
the 123 responding patients (325%) did not receive consoli-
dation treatment due to infectious complications during
induction treatment, worsening ECOG PS, co-morbidities, or
individual decision of the patient or the treating physician.
Among those 40 patients, 14 achieved CR and 26 PR. Overall
21 of 40 (522%) had a PFS-defining event (four docu-
mented progressions and 17 deaths) after a short follow-up
time (median 141 months; range 15–493 months). Fifteen
of 123 (122%) responding patients received all four planned
MATRix cycles, but received no consolidation treatment.
Among those 15 patients, six achieved CR and nine PR.
Eight of 15 patients (53%) had a PFS-defining event (two
documented progressions, six deaths) after a short follow-up
time (median 139 months; range 35–456 months).
Progression-free and overall survival
After an estimated median follow-up of 274 months (95%
CI 244–319), 100/156 patients were alive. Median PFS was
421 months (95% CI 213 to not calculable) and median OS
was not reached. The two-year PFS and OS rates were 56%
(95% CI 484–649%) and 641% (95% CI 567–725%)
respectively (Fig 2A, B). Notably, when comparing patients
regarding eligibility criteria for IELSG32 (eligible versus not
eligible), there was a substantial difference in PFS (HR 203
[95% CI 124–332]) and OS (HR 225 [95% CI 131–385]).
The respective two-year PFS and OS rates by eligibility crite-
ria were 632% (95% CI 545–734%) vs. 377% (95% CI
251–566%) and 722% (95% CI 641–814%) vs. 422%
(95% CI 288–619%) (Fig 2C, D). A similar pattern was
seen when grouping patients by eligibility defined as combi-
nation of age and ECOG PS in the sensitivity analysis (Fig-
ures S1 and S2). In a landmark analysis restricted to patients
who proceeded to a second cycle of MATRix there was no
prognostic impact of dose reduction during the first cycle on
PFS or OS. However, IELSG32 trial eligibility criteria
retained their substantial effect on PFS and OS (Table IV).
Discussion
The IELSG32 study demonstrated the efficacy and feasibility
of the MATRix protocol in an international randomized trial,
conferring significant improvements in the outcome of
Table I. Patient baseline characteristics stratified by the IELSG32














Age median (range) 60 (30–70) 70 (28–78) 62 (28–78)
Male 57 (518) 24 (522) 81 (519)
ECOG PS
ECOG 0 5 (45) 2 (43) 7 (45)
ECOG 1 55 (500) 13 (283) 68 (436)
ECOG 2 31 (282) 13 (283) 44 (282)
ECOG 3 17 (155) 12 (261) 27 (173)
ECOG 4 0 (0) 6 (130) 8 (51)
ECOG missing 2 (18) 0 (0) 2 (13)
MSKCC prognostic score
class 1 21 (191) 6 (130) 27 (173)
class 2 60 (545) 22 (478) 82 (526)
class 3 29 (264) 18 (391) 47 (301)
Histology
DLBCL 110 (100) 39 (848) 149 (955)
DLBCL – HIV associated 0 4 (87) 4 (26)





0 2 (43) 2 (13)
Country
Germany 5 (45) 4 (87) 9 (58)
Italy 23 (209) 10 (217) 33 (212)
UK 82 (745) 32 (696) 114 (731)
DLBCL = diffuse large B-cell lymphoma; ECOG PS = Eastern Cooper-
ative Group Performance Status; MSKCC = Memorial Sloan-Kettering
Cancer Center; PTLD = post-transplant lymphoproliferative disorder.
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patients with PCNSL up to the age of 70 years, as compared
to induction treatment with HD-MTX/AraC and rituximab/
MTX/AraC (Ferreri et al., 2009; Ferreri et al., 2016). Subse-
quently, the MATRix combination is a widely used induction
treatment approach at many centres for patients with newly
diagnosed PCNSL. The currently recruiting randomized
MATRix/IELSG43 trial, with similar eligibility criteria,
employs the MATRix regimen as induction treatment prior
to different consolidation approaches (NCT02531841)
(Schorb et al., 2016). However, feasibility, tolerability and
efficacy of MATRix outside a prospective trial setting have
not been assessed to date. In the present study, we show that
applying the MATRix protocol for patients with PCNSL in
routine practice can reproduce the toxicity and efficacy out-
comes similar to the IELGS32 trial: response rate 79% vs.
86%, two-year PFS 56% vs. 61%, two-year OS 641% vs.
69%, and TRM 6% in both groups. However, patients who
would have not fulfilled the IELSG32 trial inclusion criteria
(predominantly those over 70 years or with impaired ECOG
PS) were treated with lower dose intensity and experienced a
significantly inferior outcome. Of note, inter-study compar-
ison of the cohort reported herein with results from the
IELSG32 trial still needs to be considered with care; espe-
cially regarding outcomes such as lymphoma response and
PFS, which can be different, because of per protocol timing
and data quality in contrast to routine care, where some
scans may have been conducted at other time points.
Our study has a few limitations. First, patients were only
included in the study if they underwent at least one cycle of
the MATRix regimen which applies only for about 50% of
all screened patients. This number is in line with previous
publications and is mainly explained by the fact that
patients older than 65 years account for 50% of all PCNSL
cases and that those patients are likely to be considered not
eligible for intensive treatment approaches (Abrey et al.,
2000; Kasenda et al., 2015). Thus, the cohort cannot be
strictly considered an intention-to-treat population; eligibil-
ity and intention-to-treat were determined by PCNSL-expe-
rienced clinicians rather than a pre-determined protocol, we
Table II. Dose reductions of the MATRix protocol grouped by cycle and stratified by IELSG32 trial eligibility criteria. Dose reduction was defined
as at least 25% reduction of at least one MATRix component.
Cycles Inclusion criteria fulfilled (n = 110) Inclusion criteria not fulfilled (n = 46) All (n = 156) P value
One cycle delivered 12 (109) 6 (130) 18 (115) 0012
Two cycles delivered 8 (72) 12 (261) 20 (128)
Three cycles delivered 13 (118) 6 (130) 19 (122)
Four cycles delivered 77 (700) 22 (478) 99 (628)
Cycle 1 Inclusion criteria fulfilled (n = 110) Inclusion criteria not fulfilled (n = 46) All (n = 156) P value
Patients with dose reduced
25% or more
28 (255) 35 (761) 63 (404) 0001
Cycle 2 Inclusion criteria fulfilled (n = 96) Inclusion criteria not fulfilled (n = 40) All (n = 136) P value
Patients with dose reduced
25% or more
41 (427) 26 (650) 67 (493) 002918
Cycle 3 Inclusion criteria fulfilled (n = 88) Inclusion criteria not fulfilled (n = 28) All (n = 116) P value
Patients with dose reduced
25% or more
37 (420) 17 (607) 54 (466) 01317
Cycle 4 Inclusion criteria fulfilled (n = 75) Inclusion criteria not fulfilled (n = 22) All (n = 97) P value
Patients with dose reduced
25% or more
34 (453) 14 (636) 48 (495) 0205
Numbers are frequencies (column percentages).
Table III. Type of consolidation treatment stratified by IELSG32 trial
eligibility criteria for all patients irrespective of response achieved











HDT-ASCT 53 (482) 11 (239) 64 (410)




0 2 (43) 2 (13)
Lenalidomide 0 1 (22) 1 (06)
No consolidation 40 (364) 28 (609) 68 (436)
HDT-ASCT = high-dose chemotherapy with autologous stem cell
transplantation; WBRT = whole-brain radiotherapy.
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had to fully rely on the information documented in the
medical records and it remains possible that some patients
who may be ‘considered eligible’ for MATRix were treated
with other regimens. This may be partly explained by the
fact that MATRix was only adopted in routine practice in
many centres after publication of the IELSG32 trial in 2016.
Second, participating centres were experienced in treating
PCNSL patients and familiar with the MATRix protocol; 11
of 13 participating centres had enrolled and treated at least
three patients within the IELSG32 trial. This is relevant to
patient selection and may translate into clinical outcomes;
patients being treated at less experienced centres may have
an inferior prognosis. Finally, we had to rely on toxicity
assessment as documented at the respective centres during
routine care, which is different to prospective toxicity
assessment within a clinical trial. Thus, toxicity in this real-
world cohort may be underestimated.
Overall, feasibility and efficacy of the MATRix regimen in
this real-world cohort compare well with reported outcomes
from the IELSG32 trial. Notably, patients from this cohort
were older and frailer than those treated within the IELSG32
trial, with 30% of patients failing to fulfil the IELSG32 inclu-
sion criteria due to advanced age, reduced ECOG PS and/or
co-morbidities. Notably, notwithstanding an older and frailer
patient population, the TRM and stem cell mobilization rates
were comparable.
Of note, patients not fulfilling the eligibility criteria of the
IELSG32 trial could be expected to have an inferior
Table IV. Two multivariable Cox regression analyses to investigate
the prognostic impact of dose reduction (25% or more of at least
one MATRix component) during the first cycle in a landmark analy-
sis restricted to 136 patients who at least started the second cycle of






PFS Dose reduction first




met (yes versus no)
237 128–438 00061
OS Dose reduction first




met (yes versus no)
297 147–602 00025
Fig 2. (A) Progression-free survival of the whole cohort. (B) Overall survival of the whole cohort. (C) Progression-free survival of the whole
cohort stratified by the IELSG32 trial eligibility criteria. (D) Overall survival of the whole cohort stratified by the IELSG32 trial eligibility criteria.
[Colour figure can be viewed at wileyonlinelibrary.com]
Induction Therapy with MATRix in Routine Clinical Practice
ª 2020 The Authors. British Journal of Haematology published by British Society for Haematology
and John Wiley & Sons Ltd 7
prognosis compared to those meeting the trial’s inclusion
criteria. Increased age and worse ECOG PS are known to
have impact on prognosis in PCNSL (Ferreri et al., 2003b;
Abrey et al., 2006). Additionally, in patients not fulfilling the
IELSG32 trial inclusion criteria the treating physicians were
more likely to administer reduced doses during induction
treatment and only 39% of those patients underwent consoli-
dation treatment. Together, these factors are likely to explain
the inferior outcomes for IELSG32-ineligible patients. How-
ever, severe complications were mainly reported during the
first treatment course with 7% of the patients requiring
intensive-care support and 40% had dose reductions. More-
over, in our landmark analysis including all patients who
started the second cycle, dose reductions during the first
cycle did not have an impact on PFS or OS suggesting that
careful dose adjustments are feasible without compromising
treatment efficacy. This is important, because patients with
newly diagnosed PCNSL often have impaired performance
status at presentation suggesting consideration of dose reduc-
tions. However, the aim should always be to deliver all
planned courses and, importantly, consolidation treatment,
because of the substantial risk for relapse. Whether de-escala-
tion strategies in responding patients are feasible requires
further well-designed randomized trials.
We also included a small number of HIV-positive patients
in our primary analysis in whom the MATRix combination
was also shown to be feasible. Aetiology is different in this
sub-entity associated with ineffective immunoregulation of
Epstein–Barr-virus-associated B-cell proliferation. Of note,
less intensive treatment regimens in combination with
antiretroviral therapy have recently been shown to be effec-
tive (Gupta et al., 2017; Moulignier et al., 2017) and should
therefore also be considered in this particular subgroup of
PCNSL patients.
This large series underscores the feasibility and efficacy
of chemoimmunotherapy with MATRix as induction treat-
ment prior to HDT-ASCT for newly diagnosed PCNSL in
routine practice. Overall, clinical outcomes are similar to
those reported in the pivotal IELSG32 trial for those
patients fulfilling key IELSG32 trial inclusion criteria. Con-
versely, older patients with impaired performance status
experience inferior outcomes and should therefore be con-
sidered for age-adapted regimens. Importantly, for all
patients, diligent attention to supportive care and considera-
tion of dose reductions, especially during cycle 1, are
strongly recommended to mitigate against treatment-associ-
ated complications.
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Fig S1. Results from sensitivity analyses. Progression-free
survival. Eligibility defined as combination of age and ECOG
PS. In these analyses, patients were considered eligible with
age up to 65 with ECOG PS ≤3 or age up to 70 years if
ECOG PS was ≤2; all other patients were considered not eli-
gible.
Fig S2. Results from sensitivity analyses. Overall survival
Eligibility defined as combination of age and ECOG PS. In
these analyses, patients were considered eligible with age up
to 65 with ECOG PS ≤3 or age up to 70 years if ECOG PS
was ≤2; all other patients were considered not eligible.
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